The global computational biology market size was valued at USD 7.08 billion in 2025 and is projected to grow from USD 7.99 billion in 2026 to USD 21.07 billion by 2034, registering a CAGR of 12.88% during the forecast period from 2026 to 2034. North America dominated the computational biology market with a market share of 39.8% in 2025.
Computational biology is an interdisciplinary field that combines biology, computer science, mathematics, and statistics to study and analyze biological data. It uses computational tools and algorithms to understand complex biological processes, genes, proteins, cells, and organisms. Computational biology is widely used in areas such as genomics, drug discovery, disease research, personalized medicine, bioinformatics, and evolutionary studies. It helps researchers process large datasets, identify biological patterns, predict molecular interactions, and gain deeper insights into biological systems.
Download a Free Sample To learn more about this report,
AI and Machine Learning Accelerate Biological Research
The computational biology market is changing rapidly as researchers increasingly use artificial intelligence and machine learning to analyze large and complex biological datasets. These tools are being applied to protein structure prediction, drug discovery, genomics, biomarker identification, and disease research. By processing biological information faster and identifying patterns that may be difficult to detect manually, computational methods are helping researchers shorten early-stage research timelines and explore new therapeutic possibilities. This is supporting computational biology market growth across pharmaceutical, biotechnology, and academic research.
Large-Scale Biological Data Creates New Opportunities
The growing availability of genomic, molecular, and structural data is increasing the need for powerful computational platforms capable of organizing and interpreting information at scale. Researchers are combining high-performance computing, cloud platforms, and AI models to study genetic variation, protein interactions, disease pathways, and potential drug targets. These developments are contributing to the increasing computational biology market size while making data-driven research more accessible to scientists.
Growing Expansion of Large-scale Genomics Programs and Rising Biopharmaceutical R&D Expenditure Drives Market
Governments and healthcare organizations are significantly expanding national genomics programs, generating unprecedented volumes of biological data that require advanced computational analysis. Large-scale sequencing initiatives create demand for computational biology platforms capable of processing, storing, and interpreting genomic information for research and clinical applications. For example, the UK Biobank has collected genomic, imaging, and health data from 500,000 participants, while the All of Us Research Program has enrolled more than one million participants to build one of the world's largest precision medicine datasets. These population-scale programs are substantially increasing demand for computational biology software, high-performance analytics, and bioinformatics infrastructure worldwide.
High Computational Infrastructure Costs and Lack of Standardized Biological Data Restrain Market Expansion
Computational biology relies on high-performance computing infrastructure, cloud platforms, specialized software, and large-scale data storage, creating substantial operational costs for research organizations and healthcare institutions. Managing, securing, and processing massive genomic and biological datasets also require skilled personnel and advanced digital infrastructure. These financial and technical barriers limit adoption among smaller biotechnology firms, academic laboratories, and organizations with constrained research budgets.
Expansion of Precision Medicine and Rising Adoption of Computational Biology in Cell & Gene Therapy Offer Growth Opportunities to Market Players
The rapid expansion of precision medicine programs and national genomics initiatives is creating significant opportunities for computational biology solution providers. Countries are investing in large-scale genomic sequencing and population health research to improve disease prevention and personalized treatment strategies. These initiatives generate massive biological datasets requiring advanced computational analysis, creating sustained demand for bioinformatics platforms, AI analytics, and high-performance computing solutions across healthcare and life sciences.
Rapidly Expanding Biological Data and Shortage of Skilled Computational Biology & Bioinformatics Professionals Challenge Market Growth
A major challenge for the computational biology market is managing the exponential growth of genomic, proteomic, and multi-omics datasets generated through modern life sciences research. As sequencing technologies become faster and more affordable, organizations face increasing demands for scalable storage, high-performance computing, and efficient data processing. The growing volume and complexity of biological data can create computational bottlenecks, increase infrastructure costs, and slow research workflows.
Request Customizationto receive a tailored report.
Drug Discovery and Disease Modeling Segment Led the Market with a 34.7% Share in 2025
Drug discovery and disease modeling accounted for the largest share of the computational biology market in 2025, representing 34.7% and an estimated value of $3.84 billion. Computational tools help researchers study biological processes, identify potential drug targets, model disease mechanisms, and evaluate possible treatment approaches before moving into more resource-intensive laboratory and clinical work. The growing volume of biological data and advances in computational modeling are making these tools increasingly important in pharmaceutical and biotechnology research.
Cellular and biological simulation represented 28.4% of the market, valued at approximately $3.14 billion. Preclinical drug development accounted for 16.3%, while clinical trials represented 13.8%. Human body simulation software contributed 6.8%. Together, these applications show how computational biology is being used across multiple stages of biomedical research, from understanding biological systems to supporting drug development and clinical research.
Analysis Software and Services Segment is Projected to Register the Fastest Growth at a CAGR of 18.29%
Analysis software and services represented the largest tool category and are projected to register the fastest growth at a CAGR of 18.29% during 2026–2034. These tools help researchers process complex biological datasets, identify patterns, interpret genomic and molecular information, and support data-driven research. As biological datasets continue to grow in size and complexity, researchers increasingly need advanced computational capabilities to turn raw data into useful scientific insights.
Databases accounted for 31.5% of the market, representing approximately $3.48 billion, and provide researchers with access to organized genomic, molecular, clinical, and biological information. Infrastructure and hardware represented 24.2%, valued at around $2.68 billion. High-performance computing infrastructure remains important because many computational biology workloads require substantial processing and storage capacity. The continued integration of artificial intelligence and machine learning is also increasing demand for more powerful analytical environments.
In-House Segment Led the Market with a 57.6% Share in 2025
In-house computational biology services accounted for 57.6% of the market in 2025, representing approximately $6.37 billion. Pharmaceutical companies, biotechnology firms, research organizations, and academic institutions often maintain internal computational teams to keep greater control over sensitive research data, workflows, and intellectual property. Having internal capabilities can also allow researchers to customize analytical methods according to specific projects and research requirements.
Contract services accounted for the remaining 42.4% of the market, valued at approximately $4.69 billion. Outsourcing allows organizations to access specialized expertise, advanced computing resources, and analytical capabilities without building large internal teams. The contract segment is projected to grow at a faster CAGR of 18.54%, reflecting increasing interest in flexible external support for computationally intensive and specialized research projects.
Industry and Commercials Segment is Projected to Register the Fastest Growth at a CAGR of 18.18%
Industry and commercial organizations accounted for 61.3% of the computational biology market and are projected to grow at a CAGR of 18.18% during 2026–2034. Pharmaceutical and biotechnology companies are increasingly using computational methods to accelerate drug discovery, analyze biological data, identify therapeutic targets, and improve development decisions. The ability to evaluate large datasets before committing to costly laboratory experiments can help researchers make development processes more efficient.
Academic institutions represented 38.7% of the market, with an estimated value of $4.28 billion. Universities and research centers use computational biology for genomics, molecular biology, disease research, biological modeling, and other scientific investigations. Collaboration between academia and industry is also helping move computational methods from research environments into commercial drug development and biotechnology applications.
Speak to an Analystto discuss market opportunities.
North America accounted for the largest share of the global computational biology market, representing 39.8% of total revenue and reaching USD 4.40 billion in 2025. The region continues to lead due to strong investments in biotechnology and pharmaceutical research, advanced healthcare infrastructure, and widespread adoption of computational tools for drug discovery and genomics. Growing use of artificial intelligence, machine learning, and high-performance computing in life sciences is further supporting market growth.
The US market represents the largest contributor in North America, supported by strong pharmaceutical and biotechnology industries, extensive research activities, and high investments in genomics and drug discovery. Increasing adoption of AI-driven biological modeling and advanced data analysis is further strengthening market growth.
Canada's market is supported by expanding genomics research, growing biotechnology activities, and increasing investments in computational healthcare technologies. Collaboration between research institutions and life science companies is creating additional opportunities for market development.
Europe accounted for 27.6% of the global computational biology market, valued at USD 3.05 billion in 2025, and is projected to register the fastest CAGR of 18.91% during the forecast period. The regional market is driven by increasing investments in genomics, precision medicine, drug discovery, and bioinformatics. Growing adoption of artificial intelligence and cloud-based computational platforms is further accelerating market growth.
Germany's market is supported by a strong pharmaceutical and biotechnology ecosystem, advanced research infrastructure, and increasing investments in genomics and personalized medicine. Growing use of computational modeling in drug development is creating additional market opportunities.
The UK market benefits from strong life sciences research, expanding biotechnology activities, and increasing adoption of bioinformatics and computational approaches. Investments in genomics, AI, and precision medicine continue to support market expansion.
Asia Pacific accounted for 22.4% of the global computational biology market, reaching USD 2.48 billion in 2025, and is projected to grow at a CAGR of 18.36% during the forecast period. Rapid development of biotechnology, increasing healthcare investments, and expanding genomics research are driving regional market growth. Growing adoption of AI, cloud computing, and advanced data analytics in life sciences is further accelerating demand.
China's market is supported by expanding pharmaceutical and biotechnology industries, increasing genomics research, and growing investments in artificial intelligence and computational drug discovery. The development of advanced research infrastructure is further strengthening market opportunities.
Japan's market is supported by strong pharmaceutical research, advanced healthcare infrastructure, and increasing adoption of computational technologies in drug discovery and genomics. Growing focus on precision medicine is also contributing to market development.
Middle East & Africa accounted for 4.5% of the global computational biology market, totaling USD 0.50 billion in 2025. Increasing investments in healthcare infrastructure, growing biotechnology initiatives, and expanding adoption of digital health technologies are supporting market growth across the region. Rising interest in genomics and precision medicine is expected to create additional opportunities during the forecast period.
The UAE market is supported by investments in advanced healthcare infrastructure, biotechnology, and genomics. Growing adoption of AI and data-driven healthcare solutions is creating new opportunities for computational biology applications.
Africa's market is benefiting from increasing investments in genomics research, healthcare digitalization, and biotechnology infrastructure. Growing use of computational approaches for disease research, drug development, and genomic analysis is expected to create long-term growth opportunities across the region.
Unlock Regional Insightsto access country-level data, & regional trends.
June 2026: Chai Discovery signed a license agreement with Pfizer, enabling Pfizer to deploy Chai’s AI platform and gain early access to the Chai-3 model.
May 2026: QIAGEN partnered with NVIDIA to integrate NVIDIA BioNeMo and accelerated computing with QIAGEN Digital Insights’ curated bioinformatics knowledge bases.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a Healthcare Lead with over 7 years of industry experience, specializing in Healthcare IT. She provides comprehensive market insights on digital health, electronic medical records, telehealth, and healthcare analytics. Debashree’s research supports organizations in adopting technology-driven healthcare solutions, improving patient care, and achieving operational efficiency in a rapidly transforming healthcare ecosystem.
We are featured on:
sales@straitsresearch.com